Literature DB >> 25590318

State of the Art: Medical treatment of aspirin exacerbated respiratory disease (AERD).

Von Ta1, Ronald Simon.   

Abstract

Aspirin exacerbated respiratory disease (AERD) is characterized as adult onset asthma, nasal polyps, chronic rhinosinusitis, and hypersensitivity to a cyclooxygenase-1 (COX-1) inhibitor, viz aspirin or nonsteroidal antiinflammatory drugs (NSAIDs). The method for diagnosing AERD is with aspirin challenge, and treatment includes aspirin desensitization followed by continued daily aspirin. Although oral challenge has been the mainstay in the United States, lysyl-aspirin has been validated as a diagnostic tool for aspirin-sensitive asthma and will be discussed further in this article. The challenges with aspirin therapy surrounding endoscopy and perioperative aspirin therapy will be discussed. Additionally, daily aspirin therapy is not for everyone. Aspirin is relatively contraindicated in those with a history of gastrointestinal bleed and an absolute contraindication in pregnancy. Aspirin desensitization and subsequent treatment has been shown to be highly effective for AERD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25590318     DOI: 10.2500/ajra.2015.29.4114

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  6 in total

Review 1.  Chronic rhinosinusitis management beyond intranasal steroids and saline solution irrigations.

Authors:  Newton Li; Anju T Peters
Journal:  Allergy Asthma Proc       Date:  2015 Sep-Oct       Impact factor: 2.587

2.  Editorial: Advances in the diagnosis and treatment of patients with chronic rhinosinusitis and allergy.

Authors:  Jeffrey D Suh
Journal:  Am J Rhinol Allergy       Date:  2015 Jan-Feb       Impact factor: 2.467

Review 3.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

Review 4.  Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.

Authors:  Andrew A White; Taylor A Doherty
Journal:  Am J Rhinol Allergy       Date:  2018-01-01       Impact factor: 2.467

5.  Release of cyclooxygenase-2 and lipoxin A4 from blood leukocytes in aspirin-exacerbated respiratory disease.

Authors:  Ajnacska Rozsasi; Akos Heinemann; Tilman Keck
Journal:  Allergy Rhinol (Providence)       Date:  2016-01-01

6.  Multimodality and Sequential Therapy in Locally Advanced Head and Neck Cancer: A Preface to the Special Issue.

Authors:  Giuseppe Riva; Giancarlo Pecorari
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.